---
title: "Zhitong A-share lock-up release overview | March 12"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/231450253.md"
description: "According to the Zhitong Finance APP, on March 12, a total of 1 listed company had its restricted shares unlocked, with a total market value of approximately 61.9667 million yuan. The specific situation of the restricted share unlock today is as follows: Stock Abbreviation Stock Code Restricted Share Type Unlocked Shares GLORIA PHARMA 002437 Equity Incentive Restricted Circulation 28.9564 million"
datetime: "2025-03-12T01:01:02.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/231450253.md)
  - [en](https://longbridge.com/en/news/231450253.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/231450253.md)
---

# Zhitong A-share lock-up release overview | March 12

According to the Zhitong Finance APP, on March 12, a total of 1 listed company had its restricted shares unlocked, with a total market value of approximately 61.9667 million yuan.

The specific situation of the restricted share unlock today is as follows:

Stock Abbreviation

Stock Code

Restricted Share Type

Unlocked Shares

GLORIA PHARMA.

002437

Equity Incentive Restricted Circulation

28.9564 million

### Related Stocks

- [002437.CN](https://longbridge.com/en/quote/002437.CN.md)

## Related News & Research

- [Dear Cerebras Stock Fans, Mark Your Calendars for August 12](https://longbridge.com/en/news/295254870.md)
- [SHUKRAPHAR: Strong revenue and profit growth in Q1 FY27, with robust performance in the pharmaceutical segment](https://longbridge.com/en/news/295639972.md)
- [Dear Intel Stock Fans, Mark Your Calendars for August 12](https://longbridge.com/en/news/295566127.md)
- [Keymed Biosciences says Phase II trial of CM512 meets endpoints in chronic rhinosinusitis with nasal polyps](https://longbridge.com/en/news/295337751.md)
- [Revive Therapeutics Reports Positive Results from DRDC Bucillamine Nerve-Agent Research Study](https://longbridge.com/en/news/295661585.md)